🇺🇸 Clindamycin + primaquine in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 1
Most-reported reactions
- Condition Aggravated — 1 report (100%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Clindamycin + primaquine approved in United States?
Clindamycin + primaquine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Clindamycin + primaquine in United States?
McGill University Health Centre/Research Institute of the McGill University Health Centre is the originator. The local marketing authorisation holder may differ — check the official source linked above.